Baja Ventures Group

Compounding Pharmacy · Phase 1

1
Pharmacy connection to TJ Med Spa
Portfolio Connection
Active

Directly adjacent to TJ Medical Spa — sources and provides the compounds and products prescribed by TJ Medical Spa's on-staff physician. Also serves Las Rocas' spa and patients to a lesser degree.

2
Compounding pharmacy market growth
Market Opportunity
Active

Compounding pharmacy business in Mexico is growing at a CAGR of 25% to 30%. By controlling our own compounding pharmacy, we increase profitability on compounded products from 30% to 90%.

3
Pharmacy revenue streams
Revenue Model
Active

Serves TJ Medical Spa and Las Rocas spa/patients with compounded products. Also provides regular pharmacy business to retail customers, emphasizing products for US customers, increasing revenue.

4
COFEPRIS regulatory approval
Regulatory Advantage
Active

COFEPRIS-licensed compounding pharmacy. Mexico allows compounds that are restricted in the USA, giving us a significant competitive edge.

5
Supply chain quality control
Supply Chain Control
Active

Vertical integration from peptide sourcing through compounding to patient dispensing. End-to-end quality control eliminates third-party dependencies.

6
Pharmacy leadership team
Leadership
Active

Licensed pharmacists with expertise in compounding. PGVL corporate management provides operational oversight.

7
Corporate structure
Corporate Structure
Active

US Reg D 506(c) under PGVL umbrella. Part of the Baja Ventures portfolio. HK parent company, MX local corporate S.A.

8
Investment growth chart
Investment Thesis
Phased

Portfolio exposure to all Baja ventures. Points in all projects. First-look access to Phase 2 and Phase 3. TBD ROI, disbursements 8 months post-launch.

Regulation D Rule 506(c) Disclosure

Compounding Pharmacy · Baja Ventures Group Limited

Use of Funds — $300,000 Seed Raise

  • Corporate formation & legal (HK/MX/US)$45,000
  • Reg D 506(c) filing & compliance$25,000
  • Fundraising platform & investor portal$35,000
  • Marketing & investor outreach$50,000
  • Accounting & reporting systems$20,000
  • Working capital & admin reserves$75,000
  • Contingency$50,000
TOTAL$300,000
This seed capital is for corporate and infrastructure build-out ONLY — not for project-related purchases. It establishes the fundraising infrastructure to raise subsequent project capex.
Compounding Pharmacy Project Capex
  • Project capexTBD

Risk Factors

  • Investment involves significant risk. Investors may lose their entire investment.
  • $300K seed raise does not guarantee successful fundraising for compounding pharmacy project capex.
  • Compounding pharmacy operations require specialized licenses and regulatory approvals.
  • COFEPRIS approvals may be modified, suspended, or revoked.
  • Cross-border operations subject to Mexican and US regulatory changes.
  • Pharmaceutical compounding carries inherent liability and product safety risks.
  • No guaranteed ROI. Projected returns are estimates, not guarantees.
  • Liquidity is limited — no public market exists for these securities.
  • Key person risk — success depends on licensed pharmacists and management.
  • Currency exchange risk between USD and MXN.